Summary
While numerous diagnostic tests for COVID-19 have been developed for clinical and public health use, most of them provide binary or one-dimensional information on SARS-CoV-2 infection in pursuit of speed and ease of use. As their readouts are largely dependent on the specimen collection procedure, reliable diagnosis is still difficult. Here we report the development of a prototypical method for the immunocytochemical diagnosis of SARS-CoV-2 infection using oral specimens and fluorescent nanobodies against the viral spike and nucleocapsid proteins. Our cytological approach for the detection of SARS-CoV-2 infection was validated by our finding that at least half of SARS-CoV-2 RNAs in oral specimens were localized in the cellular fraction. Mapping antigens on sampled cells provided qualitative image data to which appropriate statistical texture analysis could be applied for the quantitative assessment of SARS-CoV-2 infectious status. A comprehensive comparative analysis revealed that oral cavity swabbing by medical workers provides specimens for COVID-19 diagnosis that yield comparable diagnostic accuracy as self-collected saliva specimens. Our diagnostic strategy may enable medical workers to acquire a wealth of information on virus–human cell interactions for multifaceted insight into COVID-19.
Competing Interest Statement
S. S, M. S., H. H., K. H., R. T. -T., S. I., T. M., K. Katayama, and A. M. are inventors of patent application that covers the creation and use of VHHs fused with the fluorescent proteins.
Funding Statement
This work was supported in part by RIKEN President's Discretionary Fund (to A. M.), the COVID-19 Kitasato project (to K. Katayama), grants from the Japan Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research on Innovative Areas, Resonance Bio (15H05948 to A. M.), Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research), Japan Agency for Medical Research and Development (AMED) (20he1422004j to H. N. and 21ae0121001 to K. Katayama).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of Keio University (approval number: 20210081) and was conducted in accordance with the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. All patients provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
